| 1 |
33047859 | Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects. | 2021 Apr |
2 |
| 2 |
34624444 | An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. | 2021 Nov 20 |
2 |
| 3 |
30902820 | Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. | 2019 Jun |
4 |
| 4 |
29127458 | Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases. | 2018 Feb |
3 |